An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis
Hanyu Xin, Yuan Zhong, Mengze Zhang, Lianshuang Wu, Qiuju Li, Xia Li, Yanan Wu, Lu Zhang, Jing Peng, Chong Xie, Desheng Zhu, Yong Hao, Yangtai Guan, Kan Wang · 2026
Read An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis by Hanyu Xin, Yuan Zhong, Mengze Zhang, Lianshuang Wu, Qiuju Li, Xia Li, Yanan Wu, Lu Zhang, Jing Peng, Chong Xie, Desheng Zhu, Yong Hao, Yangtai Guan, Kan Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197354.txt.
Description
Hanyu Xin and co-authors build a model to predict who responds to a drug for generalized myasthenia gravis, in a 2026 paper. The drug, efgartigimod, helps many patients with a form of the disease marked by a specific antibody, but responses vary. Early prediction could guide the first treatment cycle.
The team studied thirty five patients at several centers and profiled their clinical traits and immune measures before treatment. About two thirds responded by a standard daily living score. Non responders had higher counts of natural killer cells and a trend toward lower levels of one immune signal. A model using just those two measures sorted patients well. The authors turn it into a risk score and an online calculator.
Catalog record
| CREATOR | Hanyu Xin, Yuan Zhong, Mengze Zhang, Lianshuang Wu, Qiuju Li, Xia Li, Yanan Wu, Lu Zhang, Jing Peng, Chong Xie, Desheng Zhu, Yong Hao, Yangtai Guan, Kan Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |